Genmab outlines three Phase 3 readouts and Genmab stock costs EUR 306.70

Published on 10/02/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 25.00 percent and guidance reached DKK 4.30-4.50 billion. Genmab stock costs EUR 306.70 on October 2, 2026 versus EUR 306.55.

Schwarzweiß-Reportage einer Forscherin bei der Analyse von Laborproben im Biotechlabor — Genmab A/S im dokumentarischen Schwarzweiß-Stil zeigt konzentrierte Laborarbeit an Antikörperproben, Aktie mit ISIN DK0010272202, Illustration mit AI erstellt.

Genmab expects three Phase 3 oncology readouts in the fourth quarter of 2026, while Genmab stock was trading at EUR 306.70 at Lang & Schwarz on October 2, 2026 at 3:15 p.m. CEST, up EUR 0.15 or 0.05 percent versus the prior close of EUR 306.55. Boerse Express reported on September 28, 2026 that the programs involve EPKINLY, Rina-S and petosemtamab.

Three late-stage readouts

The EPKINLY combination is being studied with R-CHOP in first-line diffuse large B-cell lymphoma. Rina-S data concern platinum-resistant ovarian cancer, while petosemtamab is paired with KEYTRUDA in first-line metastatic head and neck cancer.

The pipeline timing gives Genmab a concentrated clinical catalyst for the fourth quarter. The readouts matter commercially because successful data could support planned launches from 2027, although regulatory review and clinical results remain decisive.

Revenue and guidance rise

Genmab reported first-half 2026 revenue growth of 25.00 percent and raised full-year 2026 revenue guidance to DKK 4.30-4.50 billion, according to Investing.com on September 23, 2026.

The second-quarter 2026 comparison was also favorable: earnings per share came in at USD 0.54 versus a USD 0.37 consensus estimate, while revenue reached USD 1.16 billion against USD 1.12 billion expected, MarketBeat reported on October 1, 2026. That combination puts execution and pipeline conversion ahead of the next data releases.

Dates and analyst expectations

MarketBeat counted nine Buy ratings, one Strong Buy and three Hold ratings among 13 firms, with an average 12-month price target of USD 39.50. H.C. Wainwright reiterated a Buy rating with a USD 40.00 target on September 14, 2026, according to the same MarketBeat report.

Genmab's extraordinary general meeting is scheduled for October 7, 2026, and the next quarterly earnings release is listed for November 4, 2026, according to MarketScreener. Those dates frame the near-term sequence from shareholder matters to the next reported operating update.

Price holds above prior close

At Lang & Schwarz, Genmab stock stood at EUR 306.70 in trading on October 2, 2026 at 3:15 p.m. CEST, compared with a prior close of EUR 306.55 on October 1, 2026. The modest 0.05 percent gain leaves clinical execution as the central valuation test rather than the day's price movement.

The further course of trading is shown by the continuously updated real-time quote of Genmab stock.